SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Chang S, Parker SL, Pham T, Buzdar AU, Hursting SD. Inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute, 1975-1992. Cancer. 1998; 82: 23662372.
  • 2
    Low JA, Berman AW, Steinberg SM, Lippman ME, Swain SM. Long-term follow-up for inflammatory (IBC) and non-inflammatory (NIBC) Stage III breast cancer patients treated with combination chemotherapy [abstract]. Proc Am Soc Clin Oncol. 2002; 21: 63a.
  • 3
    Cristofanilli M, Buzdar AU, Hortobagyi GN. Update on the management of inflammatory breast cancer. Oncologist. 2003; 8: 141148.
  • 4
    Buzdar AU, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN. Combined modality treatment of Stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. Surg Oncol Clin N Am. 1995; 4: 715734.
  • 5
    Perez CA, Fields JN. Role of radiation therapy for locally advanced and inflammatory carcinoma of the breast. Oncology (Huntingt). 1987; 1: 8194.
  • 6
    Ueno NT, Buzdar AU, Singletary SE, et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol. 1997; 40: 321329.
  • 7
    Rouesse J, Friedman S, Sarrazin D, et al. Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy. J Clin Oncol. 1986; 4: 17651771.
  • 8
    Rouzier R, Extra JM, Klijanienko J, et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol. 2002; 20: 13041310.
  • 9
    Aziz SA, Pervez S, Khan S, Kayani N, Azam SI, Rahbar MH. Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: a unique clinical experience. Breast J. 2001; 7: 398404.
  • 10
    Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U S A. 1992; 89: 72627266.
  • 11
    Lu W, Pochampally R, Chen L, Traidej M, Wang Y, Chen J. Nuclear exclusion of p53 in a subset of tumors requires MDM2 function. Oncogene. 2000; 19: 232240.
  • 12
    Braun S, Hepp F, Sommer HL, Pantel K. Tumor-antigen heterogeneity of disseminated breast cancer cells: implications for immunotherapy of minimal residual disease. Int J Cancer. 1999; 84: 15.
  • 13
    Burchell J, Gendler S, Taylor-Papadimitriou J, et al. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res. 1987; 47: 54765482.
  • 14
    Taylor-Papadimitriou J, D'Souza B, Burchell J, Kyprianou N, Berdichevsky F. The role of tumor-associated antigens in the biology and immunotherapy of breast cancer. Ann N Y Acad Sci. 1993; 698: 3147.
  • 15
    Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981; 47: 207214.
  • 16
    Guerin M, Gabillot M, Mathieu MC, et al. Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int J Cancer. 1989; 43: 201208.
  • 17
    Moll UM, LaQuaglia M, Benard J, Riou G. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci U S A. 1995; 92: 44074411.
  • 18
    Soussi T. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann N Y Acad Sci. 2000; 910: 121137.
  • 19
    Kandioler-Eckersberger D, Ludwig C, Rudas M, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res. 2000; 6: 5056.
  • 20
    An WG, Chuman Y, Fojo T, Blagosklonny MV. Inhibitors of transcription, proteasome inhibitors, and DNA-damaging drugs differentially affect feedback of p53 degradation. Exp Cell Res. 1998; 244: 5460.
  • 21
    Lu W, Chen L, Peng Y, Chen J. Activation of p53 by roscovitine-mediated suppression of MDM2 expression. Oncogene. 2001; 20: 32063216.
  • 22
    Roth JA, Grammer SF, Swisher SG, et al. P53 gene replacement for cancer—interactions with DNA damaging agents. Acta Oncol. 2001; 40: 739744.
  • 23
    Bykov VJ, Selivanova G, Wiman KG. Small molecules that reactivate mutant p53. Eur J Cancer. 2003; 39: 18281834.
  • 24
    Bykov VJ, Issaeva N, Shilov A, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med. 2002; 8: 282288.
  • 25
    Agrawal B, Reddish MA, Christian B, et al. The anti-MUC1 monoclonal antibody BCP8 can be used to isolate and identify putative major histocompatibility complex Class I associated amino acid sequences. Cancer Res. 1998; 58: 51515156.
  • 26
    Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes. Int Immunol. 1998; 10: 19071916.
  • 27
    Kontani K, Taguchi O, Narita T, et al. Modulation of MUC1 mucin as an escape mechanism of breast cancer cells from autologous cytotoxic T-lymphocytes. Br J Cancer. 2001; 84: 12581264.